Ratings SMAIO

Equities

ALSMA

FR0014005I80

Real-time Euronext Paris Other stock markets 03:00:03 2024-06-21 am EDT			5-day change	1st Jan Change
3.77 ^EUR	0.00%		-2.08%	+22.40%

Apr. 29	S.M.A.I.O S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 23	S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company is in a robust financial situation considering its net cash and margin position.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
Low profitability weakens the company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
SMAIO	+22.40%	21.07M	-
ELI LILLY AND COMPANY	+51.99%	798B	C+
JOHNSON & JOHNSON	-5.72%	356B	C+
MERCK & CO., INC.	+18.94%	328B	B-
ABBVIE INC.	+11.07%	304B	C+
ASTRAZENECA PLC	+17.38%	244B	B+
ROCHE HOLDING AG	+3.11%	227B	A+
NOVARTIS AG	+11.56%	216B	B-
AMGEN INC.	+7.59%	166B	C+
PFIZER, INC.	-3.65%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes